药物重新定位
药品
药物发现
代谢物
孟德尔随机化
医学
观察研究
地图集(解剖学)
药理学
计算生物学
生物
重新调整用途
生命银行
临床试验
代谢组学
生物信息学
内科学
遗传学
遗传变异
基因型
解剖
基因
生态学
作者
Jun Liu,Lies Lahousse,Michel G. Nivard,Mariska Bot,Lianmin Chen,Jan B. van Klinken,Carisha S. Thesing,Marian Beekman,Erik B. van den Akker,Roderick C. Slieker,Eveline Waterham,Carla Kallen,Irene de Boer,Ruifang Li‐Gao,Dina Vojinović,Najaf Amin,Djawad Radjabzadeh,Robert Kraaij,Louise J. M. Alferink,Sarwa Darwish Murad
出处
期刊:Nature Medicine
[Springer Nature]
日期:2020-01-01
卷期号:26 (1): 110-117
被引量:84
标识
DOI:10.1038/s41591-019-0722-x
摘要
Progress in high-throughput metabolic profiling provides unprecedented opportunities to obtain insights into the effects of drugs on human metabolism. The Biobanking BioMolecular Research Infrastructure of the Netherlands has constructed an atlas of drug-metabolite associations for 87 commonly prescribed drugs and 150 clinically relevant plasma-based metabolites assessed by proton nuclear magnetic resonance. The atlas includes a meta-analysis of ten cohorts (18,873 persons) and uncovers 1,071 drug-metabolite associations after evaluation of confounders including co-treatment. We show that the effect estimates of statins on metabolites from the cross-sectional study are comparable to those from intervention and genetic observational studies. Further data integration links proton pump inhibitors to circulating metabolites, liver function, hepatic steatosis and the gut microbiome. Our atlas provides a tool for targeted experimental pharmaceutical research and clinical trials to improve drug efficacy, safety and repurposing. We provide a web-based resource for visualization of the atlas (http://bbmri.researchlumc.nl/atlas/).
科研通智能强力驱动
Strongly Powered by AbleSci AI